Celltrion, Inc. - Product Pipeline Review - H2 2011

Global Markets Direct, November 2011, Pages: 51

Celltrion, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Celltrion, Inc. - Product Pipeline Review - H2 2011” provides data on the Celltrion, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Celltrion, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Celltrion, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Celltrion, Inc. - Brief Celltrion, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Celltrion, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Celltrion, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Celltrion, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Celltrion, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Celltrion, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Celltrion, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Celltrion, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Celltrion, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Celltrion, Inc.; Celltrion, Inc. - Key Therapeutics; Celltrion, Inc. - Pipeline Overview and Promising Molecules; Celltrion, Inc. - News; Celltrion, Inc. - Latest Updates; Celltrion, Inc. - Pipeline; Celltrion, Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
Celltrion, Inc. Snapshot
Celltrion, Inc. Overview
Key Information
Key Facts
Celltrion, Inc. – Research and Development Overview
Key Therapeutic Areas
Celltrion, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Celltrion, Inc. – Pipeline Products Glance
Celltrion, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Celltrion, Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Celltrion, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Celltrion, Inc. – Drug Profiles
CT-P05
Product Description
Mechanism of Action
R&D Progress
CT-P06
Product Description
Mechanism of Action
R&D Progress
CT-P10
Product Description
Mechanism of Action
R&D Progress
CT-P13
Product Description
Mechanism of Action
R&D Progress
CT-P14
Product Description
Mechanism of Action
R&D Progress
CT-P15
Product Description
Mechanism of Action
R&D Progress
CT-P16
Product Description
Mechanism of Action
R&D Progress
CT-P17
Product Description
Mechanism of Action
R&D Progress
CT-P19
Product Description
Mechanism of Action
R&D Progress
CT-P22
Product Description
Mechanism of Action
R&D Progress
Celltrion, Inc. – Pipeline Analysis
Celltrion, Inc. – Pipeline Products by Therapeutic Class
Celltrion, Inc. - Pipeline Products By Target
Celltrion, Inc. – Pipeline Products by Route of Administration
Celltrion, Inc. – Pipeline Products by Molecule Type
Celltrion, Inc. – Company Statement
Celltrion, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Celltrion, Inc., Deals Summary
Celltrion, Inc., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Hikma Pharmaceuticals Enters Into An Agreement With Celltrion And Celltrion Healthcare
EGIS Pharmaceuticals Enters Into Distribution Agreement With Celltrion And Celltrion Healthcare
Hospira Enters Into Co-Marketing Agreement With Celltrion
Celltrion Enters Into Co-Development Agreement With Yonsei University
Celltrion Enters Into Co-Development Agreement With CDC
MediGene Enters Into Co-Development Agreement With Celltrion
Celltrion Enters Into Co-Development Agreement With CSL
Licensing Agreements
Crucell Enters Into Research And License Agreement With Celltrion
Igeneon Amends Licensing Agreement With Celltrion
Igeneon Enters Into Licensing And Commercialization Agreement With Celltrion
Equity Offering
Celltrion Completes Private Placement Of $187 Million
Acquisition
VaxGen Acquires Remaining Stake In VaxGen-Celltrion
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Celltrion, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Celltrion, Inc. – Pipeline by Stage of Development, H2 2011
Celltrion, Inc. – Monotherapy Products in Pipeline, H2 2011
Celltrion, Inc. – Phase III, H2 2011
Celltrion, Inc. - Phase I, H2 2011
Celltrion, Inc. - Pipeline By Therapeutic Class, H2 2011
Celltrion, Inc. - Pipeline By Target, H2 2011
Celltrion, Inc. – Pipeline By Route of Administration, H2 2011
Celltrion, Inc. – Pipeline By Molecule Type, H2 2011
Celltrion, Inc., Other Locations
Celltrion, Inc., Deals Summary
Hikma Pharmaceuticals Enters Into An Agreement With Celltrion And Celltrion Healthcare
EGIS Pharmaceuticals Enters Into Distribution Agreement With Celltrion And Celltrion Healthcare
Hospira Enters Into Co-Marketing Agreement With Celltrion
Celltrion Enters Into Co-Development Agreement With Yonsei University
Celltrion Enters Into Co-Development Agreement With CDC
MediGene Enters Into Co-Development Agreement With Celltrion
Celltrion Enters Into Co-Development Agreement With CSL
Crucell Enters Into Research And License Agreement With Celltrion
Igeneon Amends Licensing Agreement With Celltrion
Igeneon Enters Into Licensing And Commercialization Agreement With Celltrion
Celltrion Completes Private Placement Of $187 Million
VaxGen Acquires Remaining Stake In VaxGen-Celltrion

List of Figures
Celltrion, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Celltrion, Inc. – Pipeline by Stage of Development, H2 2011
Celltrion, Inc. – Monotherapy Products in Pipeline, H2 2011
Celltrion, Inc. – Pipeline By Therapeutic Class, H2 2011
Celltrion, Inc. - Pipeline By Target, H2 2011
Celltrion, Inc. – Pipeline By Molecule Type, H2 2011

Customers who bought this item also bought

• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Analysis of Google Inc
• Scientific Games Corporation - Company Analysis
• SunGard - Profile - US
• eBay - Strong Execution
• Insight into Samsung Electronics' Notebook PC Business Model
• Ixia - Company Analysis
• CIBER Inc